Literature DB >> 30843374

Ceria Nanoparticles Fabricated with 6-Aminohexanoic Acid that Overcome Systemic Inflammatory Response Syndrome.

Han-Gil Jeong1, Bong Geun Cha2, Dong-Wan Kang1,3,4, Do Yeon Kim1,3,4, Wookjin Yang1,3,4, Seul-Ki Ki1,3, Song I Kim1,3, Juhee Han1,3, Chi Kyung Kim5, Jaeyun Kim2,6, Seung-Hoon Lee1,3,4.   

Abstract

Systemic inflammatory response syndrome (SIRS) is self-destructive and uncontrollable inflammatory response of the whole body triggered by infection, trauma, or a variety of severe injuries. Although reactive oxygen species play a pivotal role in the development of SIRS, the trials with conventional antioxidants have failed to improve patient outcome. Ceria nanoparticles (CeNPs) have potent, autocatalytic reactive oxygen species scavenging activities, which may have sufficient therapeutic effects for SIRS. Herein, 3 nm CeNPs are fabricated totally in aqueous phase by using 6-aminohexanoic acid (6-AHA) and their Ce3+ to Ce4+ ratio is increased to enhance antioxidative properties. The obtained 6-AHA-CeNPs demonstrate strong antioxidative and anti-inflammatory effects in various biofluids and inflammatory cells. In SIRS animal models, 6-AHA-CeNPs are demonstrated to reduce multiple organ injuries and inflammation. Moreover, 6-AHA-CeNPs decrease mortality and improve clinical scores of SIRS models. These findings suggest that 6-AHA-CeNPs have potential as a therapeutic nanomedicine for SIRS.
© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  6-aminohexanoid acid; cerium oxide nanoparticles; nanotherapeutics; reactive oxygen species; systemic inflammatory response syndrome

Mesh:

Substances:

Year:  2019        PMID: 30843374     DOI: 10.1002/adhm.201801548

Source DB:  PubMed          Journal:  Adv Healthc Mater        ISSN: 2192-2640            Impact factor:   9.933


  1 in total

1.  Ultrasmall Antioxidant Cerium Oxide Nanoparticles for Regulation of Acute Inflammation.

Authors:  Johoon Kim; Gwanui Hong; Luda Mazaleuskaya; Jessica C Hsu; Derick N Rosario-Berrios; Tilo Grosser; Park F Cho-Park; David P Cormode
Journal:  ACS Appl Mater Interfaces       Date:  2021-12-16       Impact factor: 9.229

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.